drugset / Trial / NCT01331291
Bosutinib in Adult Patients With Recurrent Glioblastoma
Phase 2
Completed
36 enrolled
Massachusetts General Hospital
Brigham and Women's Hospital · collabDana-Farber Cancer Institute · collabPfizer · collab
Non-randomizedParallel-groupOpen-labelTreatment
Summary
For many brain tumors, one reason that chemotherapy drugs might not be effective is that the drug may not be able to get into the brain tumor and kill the cancer cells. The brain is protected by a layer called the blood brain barrier. This barrier prevents substances from entering. The purpose of this research study is to determine if bosutinib can get past the blood brain barrier and into the brain tumor, and to see how well bosutinib works in killing cancer cells.
Timeline
- Start
- 2011-04
- Primary completion
- 2014-12
- Completion
- 2014-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bosutinib | Small molecule | 400 mg | Oral |